Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Give it a rest....learn how to trade.
He now wants .007
Yes, she been around for a while. I don’t know if she works like a turtle or if it the Doc that gives her the necessary documents to make the filings tooooo freaking late. I think it is the latest…. These CPAs are fast on such
Yep, ready to go.
Looks like she is definitely qualifyed>>>>>>
Jan 4, 2024 — Choe served as a Partner at STK Financial where she was responsible for the financial audit and review of domestic and international clients ...
Zia Choe, CPA - Partner - STK FINANCIAL P.C.
I think it is time that people start emailing Zia Choe at STK Financial and see what the holdup is all about!!!!
Flipper skipper you still full sheet. Otiko tells more truth then you🤣🤣🤣🤣🤣
I AM A FLIPPER.HOW MANY TIMES DO I HAVE TO SAY IT?????? 1 MILLION??I WILL RIDE WHAT I HAVE TO TRIPLE ZEROS IN THE EXPERT MARKET.I DO NOT THINK OTIKO WILL FILE BEFORE EXPERT MARKET.IMO.I WOULD LOVE TO SEE THE FILINGS BEFORE EXPERT MARKET.BECAUSE VDRM HAS BEEN MY ATM ENGINE.IT WILL PISS ME OFF TO SEE MY ATM RUN OUT OF MAKING MONEY HERE.
CARABAS Hell yea game on sign me up.
Orca why you keep saying we. You said you sold out at like.0118. Now all sudden your shares gonna hit expert market. But I thought you had none.🤫🤫🤫🤫
LOL, YOU MUST BE NEW TO VDRM.
I dont think so… lol… That’s too extreme. The Doc will update well financially, not doubt about it, the issue is the deals
OKAY.BET IS ON.SLOPS IF IT GOES EXPERT MARKET,HE GIVES ORCA $500,000.00. IF IT DOES NO GO EXPERT MARKET,THEN TAKIS BUYS SLOPS CHICKEN TRIO AT CARABAS IN NAPLES.
The accountant is getting paid to be on time
I AM 99.9% SURE THIS GOES TO EXPERT MARKET.WHERE OUR SHARES WILL BE WORTHLESS.AND OTIKOS 100 MILLION SHARES WILL BE WIPING HIS FILTHY B$TT WITH.
The silence The Doc is making now is not different back then when Dubai, Hospital deals and Nupelo recently. This CEO Is a mess, the sad part is that some of them are sooo submerged into their own shit that can’t even notice how bad actors they are. They think they are great!!! HMBL CEO is exactly the same.
Why beg me 2 trust you? That's pathetic
Mental midget What is your highest level of education?
With your track record…trust me…..nobody cares
If we get the wrong news, we won’t get delisted. Could we loose everything? Yes but delisted goes by the doc not submitting the Fins at all but we all know he is all about delays. Yes I do agree with you, I guess we will be called great prognosticators making a brilliant call as our account balances reach heights never seen. I hope you are right
The below are my thoughts and my opinion
What ever ViaDerma has disrespected it's S H's
It's SHOW TIME waiting & guessing about over
We will know something soon 1 way or the other
This investment is no different than going to a casino. Totally agree with you Slop.
It is becoming gut check time ladies and gentlemen. We are all teetering on a tight rope waiting on news. With the right news, this stock could go ballistic and break new highs and never look back. Of course with the wrong news, the stock could get delisted and deregistered and we essentially lose everything. This is not investing, this is called gambling. If we win, we'll look like great pronogsticators making a brilliant call as our account balances reach heights never seen. If we're wrong, well ... it won't be pretty.
VDRM has a good product. It has a production facility in place and the product is being produced and sold. It has licensing revenues (to be confirmed). It has sales revenues (to be confirmed). Company debt is being reduced. It has a CEO, although sporting many warts, who has a substantial amount to gain should the company become successful.
Sometimes you just have to say "What the f***." (Risky Business circa 1983). Still holding.
I know he still have time AND I a know he will deliver the fins but that delay of his, disgusting. It doesn’t justify him at all. Anyways, I am exited because I finally know how VDRM operates… All the way up to 0.03 down to double low digits!!! Year round, then afterwards, 0.013 down to low double digits for several months.
Once I get my money, I’ll flip this pig, rinse and shampoo!!! Until I get paid for the time lost in here
Dr. has to much time effort & $$ to just let it go.
D B I agree the Dr. will make it happen
$.0094 Shouldn't be too long for VDRM to start rocking. The Dr. is getting it together!
He still has time. The accountant may deliver.
The Doc can’t blame OTCMarket for delays. This is obvious something going on with him, again.
Note: This is my opinion only AND I didn’t get this from the Friend of my Friend
You are welcome.
You are most correct about the perpetual BIG IF now at about 6-8 years and counting. BUT all will be forgiven if large shipments start this month and show up in the financials.
Thanks GC. Not sure what to make of the arrangement (whether it's good deal for VDRM). Sounds like Biogenx will fund the costs of production, distribution and marketing of VitaStem. Then split the gross profit from sales 50/50 with VDRM. Sounds like Biogenx will be taking all of the risk. We'll see. At this point we are at the Doc's mercy. Over simplifying here, but if they produce and the stock price goes up, I'll be happy. As we have seen, its a big IF. Still holding.
Fast track wanted verification nothing 2 do with U
Grandmasim The post was NOT directed to you.
If we start seeing 10 & 20 mill then worry.
People in the know would be selling off.
Followers
|
615
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
74012
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |